The Importance of A Baseline Evaluation:

NCCN Guidelines for the Early Detection of Prostate Cancer

Categories: Summer/Fall 2019
The National Comprehensive Cancer Network revised its guidelines for the early detection of prostate cancer with an emphasis on a baseline evaluation and risk stratification beginning at age 45.

The recommended baseline evaluation includes considering a man’s family cancer history, history of prostate disease and screening such as earlier PSA results, race, and family or personal history of high-risk germline genetic mutations. Any of these factors could impact a man’s risk of developing prostate cancer, and thus can be used to guide early detection decisions.

For men 45-75 years old, the NCCN guidelines recommend different screening intervals based on prior PSA results. With a PSA below 1 ng/mL and a normal DRE, the NCCN guidelines suggest repeat testing every 2-4 years. For men with a PSA between 1-3 ng/mL or a normal digital rectal exam (DRE), the NCCN recommends repeat testing every 1-2 years. For men with a PSA over 3 ng/mL or a very suspicious DRE, the guidelines suggest reviewing indications for a biopsy.

For men older than 75 years who elect to undergo screening with a PSA or DRE, the NCCN suggests repeat testing every 1-4 years for patients with a PSA at or below 4 ng/mL. With a PSA higher than that, or a very suspicious DRE, a biopsy may be indicated.

The NCCN guidelines are important because many health insurance companies determine coverage based on the NCCN panel recommendations.

Subscribe to Quest

Dr. Catalona Pic With Donate Now Button